Replies to post #15 on Oxford BioMedica PLC (OXBDF)

[georgejjl]

Marcus,

I think that it would be a very smart investment for Novartis to buy Oxford BioMedica, but I think that it would be better for Oxford BioMedica shareholders if Oxford BioMedica remained independent and was able to mature and expand its pipeline of drugs.

Remember that Oxford BioMedica has a relationship with Pfizer where Pfizer is using a license from Oxford BioMedica currently in a Phase 1 trial using the 5t4 antigen in an ADC to treat various solid cancers. I believe that this trial may already be showing exceptional progress.

https://clinicaltrials.gov/ct2/show/NCT01891669?term=Adc+5t4&rank=1

Remember also that Oxford BioMedica is working with GSK on six different gene therapies.

GlaxoSmithKline (GSK)

"...Six products granted an GSK option to a non-exclusive license under our LentiVector® platform technology patents, for the development and commercialization of up to six product candidates targeting rare orphan diseases...."

- See more at: http://www.oxfordbiomedica.co.uk/our-partners/#.dpuf

Oxford BioMedica is on the forefront of a a new medicine using gene therapy to cure diseases in the 21st century.

Good luck and GOD bless,

George